Posluma (Flotufolastat F-18) offers precise PET imaging for detecting PSMA-positive prostate cancer lesions.
Human Body Imaging
Prostate cancer is the second most common cancer in men, affecting millions worldwide. Over the past few years, significant advancements have been made in understanding the disease’s biology, leading to improved diagnostic methods and more effective therapies. This article provides an overview of the current state of prostate cancer therapy, touching on both traditional and emerging treatments and the challenges faced in providing personalised care for patients.
Conventional Treatments
Emerging Treatments
Challenges in Personalised Care
Despite the advancements in prostate cancer therapy, challenges remain in providing personalised care for patients. The heterogeneity of the disease, variable treatment responses, and resistance mechanisms complicate the selection of optimal therapies. Moreover, access to cutting-edge treatments can be limited due to high costs and availability in certain regions.
[wpseo_breadcrumbs]
Posluma (Flotufolastat F-18) offers precise PET imaging for detecting PSMA-positive prostate cancer lesions.
Radium-223 dichloride, a targeted alpha therapy, effectively treats castration-resistant prostate cancer with bone metastases, improving patients' overall survival.
Lutetium-177 Vipivotide Tetraxetan - Pluvicto: Radiopharmaceutical for targeted cancer therapy. Innovative, promising, precise, advanced, therapeutic.
Prostate cancer's global impact persists; mCRPC, demanding advanced strategies, finds hope in 177Lu-PSMA targeted radioligand therapy.
Fluorine-18 Piflufolastat, a novel radiotracer, enables precise imaging of prostate cancer, enhancing diagnostic accuracy and facilitating personalied, targeted treatment approaches.
Fluorine-18 Flucicovine (Axumin) improves prostate cancer detection, enabling accurate diagnosis and targeted treatments with PET imaging.
Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.